Agios Pharmaceuticals Inc (NASDAQ:AGIO) Shares Bought by Janus Henderson Group PLC

Share on StockTwits

Janus Henderson Group PLC increased its position in shares of Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 29.6% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 32,400 shares of the biopharmaceutical company’s stock after purchasing an additional 7,400 shares during the quarter. Janus Henderson Group PLC owned approximately 0.06% of Agios Pharmaceuticals worth $2,729,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Strs Ohio acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $179,000. NewSquare Capital LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $182,000. Barrett Asset Management LLC acquired a new stake in shares of Agios Pharmaceuticals during the 2nd quarter worth about $253,000. M&T Bank Corp acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $293,000. Finally, Aperio Group LLC acquired a new stake in shares of Agios Pharmaceuticals during the 1st quarter worth about $311,000. Institutional investors and hedge funds own 93.63% of the company’s stock.

AGIO has been the subject of a number of recent analyst reports. Canaccord Genuity reiterated a “buy” rating and set a $90.00 target price on shares of Agios Pharmaceuticals in a research report on Wednesday, September 5th. Needham & Company LLC reissued a “buy” rating on shares of Agios Pharmaceuticals in a report on Thursday, August 2nd. Piper Jaffray Companies set a $125.00 price objective on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 2nd. SunTrust Banks reissued a “buy” rating and set a $123.00 price objective on shares of Agios Pharmaceuticals in a report on Monday, July 23rd. Finally, BidaskClub lowered shares of Agios Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, June 26th. Six analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $96.27.

Shares of NASDAQ AGIO traded up $2.52 during mid-day trading on Friday, hitting $65.88. The company’s stock had a trading volume of 565,766 shares, compared to its average volume of 443,725. The firm has a market capitalization of $4.47 billion, a PE ratio of -9.76 and a beta of 1.73. Agios Pharmaceuticals Inc has a one year low of $51.62 and a one year high of $99.82.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($1.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.62) by $0.43. The company had revenue of $40.40 million for the quarter, compared to analyst estimates of $12.47 million. Agios Pharmaceuticals had a negative net margin of 462.08% and a negative return on equity of 51.71%. The company’s revenue for the quarter was up 257.5% on a year-over-year basis. During the same quarter last year, the firm earned ($1.78) EPS. As a group, equities research analysts expect that Agios Pharmaceuticals Inc will post -6.11 EPS for the current year.

In other news, insider Scott Biller sold 3,000 shares of the firm’s stock in a transaction dated Friday, October 5th. The shares were sold at an average price of $69.79, for a total value of $209,370.00. Following the transaction, the insider now owns 53,932 shares of the company’s stock, valued at approximately $3,763,914.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Christopher Bowden sold 1,700 shares of the firm’s stock in a transaction dated Thursday, August 30th. The shares were sold at an average price of $80.03, for a total transaction of $136,051.00. Following the completion of the transaction, the insider now directly owns 1,224 shares in the company, valued at approximately $97,956.72. The disclosure for this sale can be found here. Insiders sold a total of 28,355 shares of company stock worth $2,148,062 in the last ninety days. Insiders own 3.02% of the company’s stock.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, engages in the discovery and development of medicines for the treatment of cancer and rare genetic metabolic disorders in the United States. It is developing IDHIFA, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein that is in Phase I/II clinical trials for patients with advanced hematologic malignancies with an IDH 2 mutation; Phase III clinical trial for patients with IDH2 mutant-positive acute myeloid leukemia (AML); Phase Ib frontline combination trial for patients with newly diagnosed AML with an IDH2 or IDH1 mutation; and Phase I/II frontline combination trial for patients with newly diagnosed AML.

Further Reading: Penny Stocks, What You Need To Know

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.